H1N1 News and Research

RSS
Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Fear of swine flu impacts lifestyle

Fear of swine flu impacts lifestyle

Roche to provide the RealTime ready Influenza A/H1N1 Detection Set to CLIA high-complexity labs under EUA

Roche to provide the RealTime ready Influenza A/H1N1 Detection Set to CLIA high-complexity labs under EUA

Email security experts at Red Condor issue a warning about latest spam campaign

Email security experts at Red Condor issue a warning about latest spam campaign

Roche ships additional quantities of Tamiflu oral suspension

Roche ships additional quantities of Tamiflu oral suspension

Respiratory syncytial virus, the most common cause of pneumonia in children

Respiratory syncytial virus, the most common cause of pneumonia in children

U.S. H1N1 cases decreasing, CDC says; HHS to review approach to health-threat preparedness

U.S. H1N1 cases decreasing, CDC says; HHS to review approach to health-threat preparedness

Officials to review U.S. health-threat response systems

Officials to review U.S. health-threat response systems

Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study

Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study

Sinovac Biotech receives fourth purchase order for its H1N1 vaccine from Chinese government

Sinovac Biotech receives fourth purchase order for its H1N1 vaccine from Chinese government

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

URAC accreditation ensures round the clock access to quality health care

URAC accreditation ensures round the clock access to quality health care

SinoFresh Healthcare re-launches sales and distribution of Sinofresh Nasal Spray

SinoFresh Healthcare re-launches sales and distribution of Sinofresh Nasal Spray

Vermont Department of Health chooses Emergency Management Software from Upp Technology

Vermont Department of Health chooses Emergency Management Software from Upp Technology

New patented technology to combat healthcare-associated infections

New patented technology to combat healthcare-associated infections

CHG Healthcare Services implements campaign to lessen the spread of H1N1 among employees

CHG Healthcare Services implements campaign to lessen the spread of H1N1 among employees

CRO to run CEL-SCI's upcoming Phase III clinical trial

CRO to run CEL-SCI's upcoming Phase III clinical trial

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

Swine flu cases appear to have peaked

Swine flu cases appear to have peaked

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.